Global Finance News
05 Nov 2026, 09:34
McKesson Raises Fiscal 2027 EPS Outlook as Q2 Revenue and Profit Growth Accelerate
McKesson (NYSE: MCK) reported fiscal second-quarter revenue of $111.0 billion, up 8% year over year, while adjusted diluted EPS increased 18% to $11.68.
Growth was led by North American Pharmaceutical and Oncology & Multispecialty. North American Pharmaceutical revenue rose 6% to $91.4 billion, while adjusted segment operating profit increased 22%. Oncology & Multispecialty revenue climbed 24% to $15.0 billion.
Prescription Technology Solutions revenue increased 10%, while adjusted operating profit rose 18%. Medical-Surgical Solutions revenue grew 5%, although adjusted operating profit declined 10% due to weaker ambulatory-care mix.
McKesson generated $3.1 billion of operating cash flow and $2.9 billion of free cash flow during the quarter. In the first half of the fiscal year, the company returned $3.6 billion to shareholders, including $3.4 billion through share repurchases.
The company also raised fiscal 2027 adjusted EPS guidance to $45.60-$46.40 from $44.20-$45.00, implying growth of 17%-19%.
McKesson continues to expand its specialty and community-care footprint, including its planned investment in Option Care Health, the acquisition of Precision Medicine Group and an extended pharmaceutical distribution agreement with CVS Health through 2032.
McKesson (NYSE: MCK) reported fiscal second-quarter revenue of $111.0 billion, up 8% year over year, while adjusted diluted EPS increased 18% to $11.68.
Growth was led by North American Pharmaceutical and Oncology & Multispecialty. North American Pharmaceutical revenue rose 6% to $91.4 billion, while adjusted segment operating profit increased 22%. Oncology & Multispecialty revenue climbed 24% to $15.0 billion.
Prescription Technology Solutions revenue increased 10%, while adjusted operating profit rose 18%. Medical-Surgical Solutions revenue grew 5%, although adjusted operating profit declined 10% due to weaker ambulatory-care mix.
McKesson generated $3.1 billion of operating cash flow and $2.9 billion of free cash flow during the quarter. In the first half of the fiscal year, the company returned $3.6 billion to shareholders, including $3.4 billion through share repurchases.
The company also raised fiscal 2027 adjusted EPS guidance to $45.60-$46.40 from $44.20-$45.00, implying growth of 17%-19%.
McKesson continues to expand its specialty and community-care footprint, including its planned investment in Option Care Health, the acquisition of Precision Medicine Group and an extended pharmaceutical distribution agreement with CVS Health through 2032.
